These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31220470)

  • 61. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma.
    Liu Y; Jiang P; Wang G; Liu X; Luo S
    Eur J Surg Oncol; 2018 Jul; 44(7):1087-1093. PubMed ID: 29764705
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma.
    Zhang L; Jia G; Shi B; Ge G; Duan H; Yang Y
    Cell Physiol Biochem; 2016; 40(3-4):757-769. PubMed ID: 27915333
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MiR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma.
    Yan TH; Qiu C; Sun J; Li WH
    Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3038-3046. PubMed ID: 29863248
    [TBL] [Abstract][Full Text] [Related]  

  • 65. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
    Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma.
    Xiong Y; Hu B; Wei L; Jiang D; Zhu M
    Tumour Biol; 2015 Dec; 36(12):9579-88. PubMed ID: 26141041
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.
    Bai B; Lin Y; Hu J; Wang H; Li L; Zhao S; Zhang J; Meng W; Yue P; Bai Z; Li X
    Oncol Rep; 2019 Mar; 41(3):1539-1548. PubMed ID: 30747220
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potential dual functional roles of the Y-linked RBMY in hepatocarcinogenesis.
    Kido T; Tabatabai ZL; Chen X; Lau YC
    Cancer Sci; 2020 Aug; 111(8):2987-2999. PubMed ID: 32473614
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overexpression of Ubiquitin-Specific Protease15 (USP15) Promotes Tumor Growth and Inhibits Apoptosis and Correlated With Poor Disease-Free Survival in Hepatocellular Carcinoma.
    Yao XQ; Li L; Piao LZ; Zhang GJ; Huang XZ; Wang Y; Liang ZL
    Technol Cancer Res Treat; 2020; 19():1533033820967455. PubMed ID: 33267707
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Takahashi Y; Ueda M; Sakimura S; Uchi R; Kurashige J; Takano Y; Nanbara S; Komatsu H; Saito T; Shinden Y; Iguchi T; Eguchi H; Atsumi K; Sakamoto K; Doi T; Hirakawa M; Honda H; Mimori K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1402-9. PubMed ID: 25404478
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
    Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
    Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
    Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
    J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
    Gong SJ; Feng XJ; Song WH; Chen JM; Wang SM; Xing DJ; Zhu MH; Zhang SH; Xu AM
    Cancer Biol Ther; 2016; 17(2):151-62. PubMed ID: 26618405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells.
    Guo Z; Chen L; Zhu Y; Zhang Y; He S; Qin J; Tang X; Zhou J; Wei Y
    Oncol Rep; 2012 Feb; 27(2):396-402. PubMed ID: 22075935
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma.
    Qiu H; Zhang X; Ni W; Shi W; Fan H; Xu J; Chen Y; Ni R; Tao T
    Dig Dis Sci; 2016 Mar; 61(3):795-805. PubMed ID: 26553251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value.
    Evert M; Frau M; Tomasi ML; Latte G; Simile MM; Seddaiu MA; Zimmermann A; Ladu S; Staniscia T; Brozzetti S; Solinas G; Dombrowski F; Feo F; Pascale RM; Calvisi DF
    Br J Cancer; 2013 Nov; 109(10):2654-64. PubMed ID: 24136149
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.